Eurobio Scientific has completed its $170 million acquisition of the Lab Products division of CareDx, Inc., following Swedish regulatory clearance. The transaction closed on 30 June 2026.
The acquired business includes CareDx AB in Sweden and its subsidiaries in the United States and Australia. It will be combined with Eurobio’s GenDx affiliate, strengthening its presence in transplantation diagnostics in the United States, Europe and Asia-Pacific.
Kahn Partners acted as lead M&A counsel to Eurobio Scientific.